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Activated hepatic stellate cells (HSC) participate in
matrix remodeling and deposition in liver fibrosis. The
present study demonstrates that interleukin (IL)-10 is
expressed by HSC upon activation in vitro or in vivo and
that autocrine effects of this cytokine include inhibition
of collagen production. Culture activation of HSC
caused a distinct increase in IL-10 mRNA level com-
pared with freshly isolated quiescent HSC. Treatment of
cultured HSC with tumor necrosis factor-a, transform-
ing growth factor-b, or lipopolysaccharide further in-
creased IL-10 mRNA by 2-fold and resulted in the release
of IL-10 protein into the medium. HSC isolated from rats
after bile duct ligation (BDL) showed prominent in-
creases in IL-10 mRNA (3 100) and protein (3 30) levels
at 7 days after BDL, but such induction disappeared in
advanced liver fibrosis (19 days after BDL). IL-10 expres-
sion correlated positively with mRNA expression of in-
terstitial collagenase and inversely with that of a1(I)
collagen. Addition of anti-IL-10 IgG to cultured HSC
caused enhanced collagen production under a basal or
stimulated condition with TGF-b, tumor necrosis fac-
tor-a, or lipopolysaccharide. These effects were associ-
ated with increased a1(I) collagen mRNA and recipro-
cally reduced collagenase mRNA levels. Co-transfection
of HSC with an IL-10 expression vector and collagen
reporter genes showed a 40% inhibition of a1(I) collagen
promoter activity. These results demonstrate that acti-
vation of HSC causes enhanced autocrine expression of
IL-10 which possesses a negative autoregulatory effect
on HSC collagen production mediated at least in part by
a1(I) collagen transcriptional inhibition and stimula-
tion of collagenase expression. These findings, along
with the demonstrated early induction of HSC IL-10 ex-
pression and its late disappearance during biliary liver
fibrosis, suggest its in vivo role in matrix remodeling
and a possibility that failure for HSC to sustain IL-10
expression underlies pathologic progression to liver
cirrhosis.
Hepatic stellate cells (HSC)1 are vitamin A-storing perisinu-
soidal cells in the liver. These cells participate in matrix re-
modeling and wound healing of the liver via their myofibro-
blastic activation (see Ref. 1 for review). Several plausible
mechanisms have been proposed which underlie HSC activa-
tion (1). One such mechanism involves soluble factors such as
cytokines and inflammatory mediators, which seem to induce
different aspects of the cellular activation. Fox example, plate-
let-derived growth factor, IL-1, TNF-a, TGF-a are all mitogenic
to HSC (2, 3), while TGF-b is a potent fibrogenic cytokine that
not only induces expression of matrix genes (3–5) and tissue
inhibitors of metalloprotease (TIMP) (6), but may also confer
HSC a myofibroblastic phenotype by up-regulating a-smooth
muscle actin expression (7, 8). These soluble factors are re-
leased by effector cells such as hepatic macrophages (9–11),
endothelial cells (12), hepatocytes (13), or platelets (14) to es-
tablish a paracrine mode of action or produced by HSC to
achieve autocrine effects (15). It also seems important to rec-
ognize that one of the primary activities of many of these
cytokines resides in their modulation of inflammation and im-
mune responses. As integral part of wound repair processes,
monocytes, fibroblasts, and myofibroblasts are recruited to the
injury site by platelet-derived growth factor (16) and TGF-b
(17). HSC are shown to express MCP-1 (18), which chemoat-
tracts monocytes; M-CSF (19), which induces proliferation and
differentiation of monocytes; PAF (20) and CINC (21), which
recruit neutrophils; and ICAM (22), which causes adhesion and
transmigration of neutrophils. Thus, HSC may also actively
participate in regulation of inflammation in the liver.
IL-10 is a cross-regulatory cytokine produced by Th2 cells,
macrophages, mast cells, and B cells. It mediates several key
functions of multiple cell types. IL-10 inhibits functions of Th1
cells and their expression of IL-2 and g-interferon (23), sup-
presses macrophages, including antigen presentation to Th1
cells, cytokine production, and cytotoxic activities (24, 25). In
contrast, IL-10 stimulates mast cells (26) and B cells (27). In
addition, IL-10 has been shown recently to down-regulate type
I collagen gene expression and to increase matrix metallopro-
tease-1 (interstitial collagenase) and matrix metalloprotease-3
(stromelysin-1) (MMP-1 and -3) expression in cultured skin
fibroblasts, suggesting a role of IL-10 in the breakdown and
remodeling of the extracellular matrix (28). In contrast, exog-
enous IL-10 inhibits synthesis of MMP-9 (92-kDa gelatinase)
and blocks LPS-stimulated MMP-1 expression by human
macrophages while it stimulates their TIMP-1 production (29).
Thus, these findings suggest fibrogenic effects of IL-10 on
macrophages, which seem to oppose the aforementioned effects
on fibroblasts.
* This work was supported by National Institutes of Health Grants
AA06603 (to H. T.) and AA10459 (to R. A. R.) and by the Medical
Research Service of Department of Veterans Affairs (to H. T.) and USC
Research Center for Liver Disease Molecular Biology Core Facility
Grant P30-DK-48522. The costs of publication of this article were de-
frayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
¶ To whom all correspondence and reprint requests should be ad-
dressed: Division of GI and Liver Diseases, USC School of Medicine,
2011 Zonal Ave., HMR-101, Los Angeles, CA 90033-4581. Tel.: 213-342-
5107; Fax: 213-342-5425; E-mail: htsukamo@hsc.usc.edu.
1 The abbreviations used are: HSC, hepatic stellate cells; IL, inter-
leukin; TNF, tumor necrosis factor; TGF, transforming growth factor;
TIMP, tissue inhibitors of metalloprotease; MMP, matrix metallopro-
tease; LPS, lipopolysaccharide; BDL, bile duct ligation; RT-PCR, re-
verse transcription-polymerase chain reaction; bp, base pair(s).
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 273, No. 1, Issue of January 2, pp. 302–308, 1998
Printed in U.S.A.
This paper is available on line at http://www.jbc.org302
This is an Open Access article under the CC BY license.
In this report, we demonstrate for the first time, induced
expression of IL-10 by rat HSC upon activation in vitro by
culturing on plastic dish and in vivo by cholestatic liver injury.
IL-10 expression by HSC is up-regulated by TNF-a and TGF-b1
in vitro and induced conspicuously during the early phase of
cholestatic injury followed by a disappearance of the induction
at the late fibrogenic phase. In vitro neutralization experi-
ments demonstrate autocrine stimulation of interstitial colla-
genase expression and inhibition of a1(I) collagen expression
by IL-10 in HSC, suggesting its role in initiation of matrix
remodeling.
MATERIALS AND METHODS
Cholestatic Liver Injury—Cholestatic liver injury was induced in
male Wistar rats weighing 500–600 g by aseptic ligation and transec-
tion of the common bile duct (BDL) as described previously (30). An-
other group of the rats was sham-operated to serve as controls (Sham).
The animal protocol described in this study was approved by the Insti-
tutional Care and Use Committee of the University of Southern
California.
HSC Isolation and Culture—HSC were isolated from normal male
Wistar rats, BDL, and Sham animals by in situ digestion of the liver
and arabinogalactan gradient ultracentrifugation as reported previ-
ously (31, 32). The purity and the viability of the cells from all animals
exceeded 98 and 97%, respectively. The cells from normal rats were
cultured in RPMI with 10% fetal calf serum in 24-well plates for 5–6
days after isolation. For experiments testing effects of TNF-a (0.1–10
ng/ml), TGF-b (0.1–10 ng/ml), LPS (1–100 mg/ml), and anti-IL-10 IgG
(20 mg/ml), the cells were washed with phosphate-buffered saline twice
and incubated with serum-free RPMI and test substances for 42 h.
TNF-a, TGF-b, and goat anti-mouse IL-10 IgG were purchased from R
& D System (Minneapolis, MN), and LPS and non-immune goat IgG
were from Sigma.
RNA Extraction, RT-PCR—Total RNA was extracted from freshly
isolated and cultured cells by a method of Chomczynski and Sacchi (33).
For RT-PCR, total RNA was reverse-transcribed using 600 units of
Moloney murine leukemia virus reverse transcriptase and oligo(dT) at
37 °C for 60 min. The synthesized cDNA for IL-10, interstitial collagen-
ase, a1(I) collagen, and b-actin were amplified using specific sets of
primers designed from published cDNA sequences (34–36) as follow:
IL-10, CTGGCTCAGCACTGCTAT and ATTCATGGCCTTGTAGACAC;
rat interstitial collagenase, CGAACACTCAAATGGTCCCA and TCCA-
CATGGTTGGGAAGTTC; collagen a1(I), ACAGCACGCTTGTGGAT
and GTCTTCAAGCAAGAGGACCA; b-actin, GAGCTATGAGCTGCCT-
GACG and AGCACTTGCGGTCCACGATG. A competitive template
containing the specific primer sequences for IL-10 was constructed
using a PCR MIMIC™ (CLONTECH). For competitive PCR, sample
cDNA was amplified in the presence of the increasing amount of the
competitor (5 3 10221 to 1.6 3 10219 mol). The mRNA quantity was
assessed by calculating the amount of the competitor added to achieve
an equimolar amount of the PCR products of the competitor and IL-10.
IL-10 cDNA Fragment Subcloning and Sequencing—The 475-bp
IL-10 cDNA fragment generated by PCR was isolated from 1.5% agar-
ose gel with an elution buffer (0.5 M ammonium acetate, 10 mM mag-
nesium acetate, 1 mM EDTA, 0.1% SDS, pH 8.0). The eluted cDNA was
ligated into a PCR™ vector from a TA cloning kit (Invitrogen Corp., San
Diego, CA). After a large scale plasmid preparation, the sequence of the
cDNA was determined by the chain termination method (U. S. Bio-
chemical Corp.). A partial EcoRI fragment (326 bp) of the cDNA insert
was purified from agarose gel as described above and used as a probe for
Northern blot hybridization.
Northern Blot Analysis—For Northern blot analysis for IL-10, 10 mg
of total RNA was electrophoresed in 1% agarose gel containing formal-
dehyde and transferred to nylon filter (Micron Separations, Westboro,
MA) as described (31). The 326-bp IL-10 cDNA fragment was labeled
with [a-32P]dCTP using a random primer labeling kit (Life Technolo-
gies, Inc.). Prehybridization, hybridization, washing, and autoradiogra-
phy were performed as described previously (31). Equivalent RNA
loading was confirmed by rehybridization of the filter for 18 S rRNA.
Enzyme-linked Immunosorbent Assay and Western Blot Analysis—
For determination of the IL-10 concentration in the HSC culture me-
dium, the media from three wells were combined, dialyzed, lyophilized,
and analyzed for IL-10 using a mouse IL-10 enzyme-linked immunosor-
bent assay kit (Quantikine™, R & D Systems). To detect IL-10 in HSC,
Western blot analysis was performed. Freshly isolated HSC were sub-
jected to protein extraction using a 2 3 lysis buffer (100 mM Tris-HCl,
pH 6.8, 4% SDS, 20% glycerol, and 2% b-mercaptoethanol). Samples
(100 mg of protein per each sample) were separated by 8% polyacryl-
amide gel electrophoresis using reducing conditions and transferred to
nitrocellulose filters (Bio-Rad). The filters were first treated with 10%
non-fat milk in 20 mM Tris base, pH 7.6, 137 mM NaCl, and 0.1% Tween
20 (TBST) and incubated with goat polyclonal anti-mouse IL-10 anti-
bodies (R & D Systems) at 1:300 dilution in TBST with 1% bovine serum
albumin, followed by incubation with rabbit anti-goat IgG antibodies
(1:2000) conjugated with horseradish peroxidase. The immobilized IL-
10-antibody complex was detected by chemiluminescence using ECL kit
(Amersham Corp.).
Collagen Synthesis Assay—To examine whether neutralization of
IL-10 produced by HSC affects collagen production, the cultured cells
were incubated for 48 h with serum-free RPMI with ascorbic acid (50
mg/ml) and b-aminopropionitrile fumarate (50 mg/ml) in the presence of
anti-IL-10 IgG or nonimmune IgG (20 mg/ml) and incubated with
[2,3,4,5-3H]proline (10 mCi/ml) for the last 18 h to radiolabel newly
synthesized collagen (3). The cell and media proteins were precipitated
with 10% trichloroacetic acid. Collagen production was determined by a
collagenase digestion method (37).
Transfection and Reporter Gene Assays—To examine whether IL-10
has any effects on collagen gene promoter activity, cultured HSC after
the first passage were transiently co-transfected with a collagen re-
porter gene plasmid (pGLCO2 or pGLCO3) (38) and a murine sense or
antisense IL-10 expression vector (39), which was kindly provided by
Dr. Lili Feng at the Scripps Research Institute. The collagen reporter
gene, pGLCO2, contains 2200 bp of the murine a1(I) collagen gene
59-flanking region linked to the luciferase reporter gene, while pGL-
COL3 contains 220 bp of a1(I) collagen gene 59-flanking region. Lipo-
somes were prepared using 3 mg of a reporter gene plasmid and 5 mg of
the expression vector along with 32 ml of LipofectAMINE reagent (Life
Technologies, Inc.). The cells were incubated with the liposomes for 8 h,
the liposome mixture removed, and fresh medium containing 10% fetal
calf serum added. The cells were incubated for additional 36 h, washed
with phosphate-buffered saline, and lysed for luciferase assay as de-
scribed previously (38).
Statistical Analysis—All data are expressed as means 6 S.E. The
significance for the difference between the groups was assessed using
standard t test. For quantification of competitive RT-PCR data, a linear
regression analysis was performed between the concentration of the
competitive template used in the assay and the ratio of densitometric
results for the competitor product over than of the target gene product.
RESULTS
IL-10 RT-PCR for Cultured HSC—RT-PCR analysis of RNA
from freshly isolated HSC from normal rats showed no detect-
able product for IL-10 using 35 cycles of amplification (first
lane, Fig. 1 (upper panel)). However, HSC cultured on plastic
wells for 7 days showed an increase in IL-10 mRNA as indi-
cated by a detectable PCR product (second lane, Fig. 1 (upper
panel)). Furthermore, incubation of HSC with TNF-a or TGF-b,
cytokines known to stimulate HSC (3), caused further in-
creases in IL-10 mRNA (lane 3–8, Fig. 1 (upper panel)). Semi-
quantitative analyses of the RT-PCR results were performed by
scanning densitometry of the IL-10 PCR product and standard-
ization with b-actin results (Fig. 1, lower panel). These analy-
ses show 2-fold increases in IL-10 mRNA expression by TGF-b
(10 ng/ml) or TNF-a (10 ng/ml) and a 50% increase by LPS (10
mg/ml).
IL-10 Release by Cultured HSC—To assess the levels of IL-10
released by cultured HSC following treatment with several
agonists, and enzyme-linked immunosorbent assay was per-
formed on the medium samples (Table I). No detectable IL-10
was measured in the medium from untreated HSC. However,
TNF-a, TGF-b, and LPS all stimulated IL-10 release by HSC.
HSC IL-10 mRNA Expression in Cholestatic Liver Inju-
ry—To determine whether IL-10 is expressed by HSC during
the course of cholestatic liver injury, HSC were isolated from
rats at 2, 7, and 19 days after bile duct ligation or sham
operation, and RT-PCR was performed on HSC RNA samples
for detection of IL-10 mRNA (Fig. 2). Sham HSC show unde-
tectable or minimal IL-10 mRNA levels at each time point. In
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contrast, HSC from BDL show a distinct increase in IL-10
mRNA at 2 days, which was further accentuated at 7 days.
Interestingly, this induction of IL-10 mRNA expression was
completely abrogated at 19 days. To quantitatively assess the
induction at 7 days, competitive PCR was performed using a
specifically constructed competitive template. As shown in the
upper panel of Fig. 3A, addition of an increasing amount of the
competitor (from right to left) resulted in a progressive reduc-
tion in the level of IL-10 PCR product from the Sham sample
while reciprocally raising the level of the competitor product.
For the BDL samples, which are expected to have much lower
levels, 40 cycles of amplification was used. Even though the
level of IL-10 product was still lower, the similarly effective
competition by the competitor was shown but with the amounts
of the competitor that were approximately 2 orders of magni-
tude lower than those used for Sham. Linear regression anal-
ysis was performed for three pairs of competitive PCR data
(Fig. 3B). As predicted, the level of IL-10 mRNA in 7-day BDL
HSC was 100-fold higher than that in Sham HSC.
Subcloning and Sequencing of IL-10 PCR Product—To verify
that the PCR product detected was truly a IL-10 cDNA frag-
ment, we subcloned the product into a TA vector and sequenced
a partial EcoRI fragment (326 bp) following a large scale plas-
mid preparation and cDNA purification. The sequence of the
fragment showed a perfect match with the published nucleotide
sequence of rat IL-10 cDNA (34), demonstrating that our PCR
indeed detected IL-10 mRNA in HSC. Furthermore, we have
utilized the purified 326-bp IL-10 cDNA fragment as a probe to
perform Northern blot analysis on HSC RNA samples. North-
ern blot analysis clearly confirmed prominent induction of
IL-10 mRNA expression in HSC from 7-day BDL as compared
with corresponding Sham (Fig. 4).
Detection of IL-10 Protein in Activated HSC—Western blot
analysis was performed to examine whether IL-10 protein level
is coordinately increased in HSC from 7-day BDL (Fig. 5). The
analysis detected an immunoreactive band with a distinct in-
creased intensity in BDL (last two lanes), which corresponded
to the molecular size (17 kDa) of authentic recombinant mouse
IL-10 standard (first lane). As an internal control, desmin was
immunoblotted using the same samples, which showed the
relatively similar immunoreactivity between the two groups of
the samples (bottom panel).
Relationship of IL-10 Expression to Collagen or Collagenase
Expression in BDL—We were very intrigued by the time-de-
pendent induction of IL-10 in HSC at 7 days in BDL animals.
Since recent studies suggested regulation of collagen and col-
lagenase genes by IL-10 in other cell types (28, 29), we exam-
ined a1(I) collagen and interstitial collagenase mRNA expres-
sion in the same HSC RNA samples used for IL-10 RT-PCR
analysis (Fig. 2, lower two panels). Induction of interstitial
collagenase mRNA expression was shown to coincide with that
of IL-10 at 7 days as was the disappearance of induction of both
genes at 19 days. On the contrary, marked induction of a1(I)
collagen expression occurred when IL-10 expression ceased at
19 days.
FIG. 1. Upper panel, IL-10 mRNA expression by culture activated
HSC. IL-10 mRNA expression in HSC was assessed by RT-PCR.
Freshly isolated HSC show very low levels of IL-10 (first lane), whereas
culture-activated HSC grown in plastic dish for 6 days expressed ap-
preciably more IL-10 mRNA (second lane). Treatment of cultured HSC
with TNF-a and TGF-b further increased IL-10 mRNA levels (third to
eighth lanes). Lower panel, densitometric analysis of IL-10 mRNA ex-
pression by cultured HSC. Densitometric RT-PCR data for IL-10 mRNA
were standardized with b-actin signals and statistically compared be-
tween different treatment groups. Treatment of cultured HSC with
TNF-a (10 ng/ml) and TGF-b (10 ng/ml) resulted in significant 2-fold
increases in IL-10 mRNA expression, while LPS (10 mg/ml) caused a
40% increase. *, p , 0.05 as compared with control.
TABLE I





1 2 3 4
pg/well pg/well
TNF-a (10 ng/ml) 16.56 33.95 28.22 28.77 26.88 6 3.67a
TGF-b (10 ng/ml) 17.3 11.46 13.23 14.56 14.14 6 1.23a
LPS (10 mg/ml) 4.6 NDb 13.89 18.73 12.41 6 4.15c
Control UDd UD UD UD UD
a p , 0.05.
b ND, not determined.
c p 5 0.09.
d UD, undetected.
FIG. 2. IL-10 mRNA expression in HSC isolated from rats with
cholestatic liver injury. IL-10 RT-PCR analysis was performed with
HSC isolated from rats at 2 days, 7 days, and 19 days after ligation of
bile duct (BDL) (B) or sham operation (S). IL-10 mRNA expression in
HSC is slightly and prominently enhanced in BDL animals at 2 and 7
days, respectively, while such induction disappeared at 19 days. RT-
PCR also demonstrates time-dependent induction of interstitial colla-
genase mRNA expression by HSC at 7 days after BDL, which coincides
with IL-10 mRNA expression. a1(I) collagen mRNA levels were mildly
increased in HSC from BDL animals at 7 days, followed by its more
accentuated increase at 19 days when IL-10 expression ceased.
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IL-10 Neutralization Enhances HSC Collagen Production—
The above results suggested a possible link between IL-10
expression by activated HSC and matrix homeostasis. To ex-
amine this possibility, collagen production was assessed by
incorporation of [3H]proline with cultured HSC exposed to
FIG. 4. Northern blot analysis for IL-10 mRNA. Using PCR-
cloned IL-10 cDNA, we have performed Northern blot analysis on two
sets of RNA samples. This analysis confirmed the prominent increase in
IL-10 mRNA level in HSC from BDL animals.
FIG. 5. Western blot analysis of HSC protein extracts for IL-10.
HSC protein extracts (100 mg each lane) prepared from Sham and BDL
animals were analyzed for IL-10 by Western blot analysis and a chemi-
luminescence detection method as described under “Materials and
Methods.” Note distinctly increased levels of IL-10 in BDL samples as
compared with Sham samples. The lower panel shows desmin immu-
noblotting with relatively equal levels of this cytoskeletal protein in all
four samples, indicating equal protein loading.
FIG. 6. IL-10 neutralization stimulates HSC collagen produc-
tion. Cultured HSC were incubated with anti-IL-10 IgG (20 mg/ml) or
nonimmune IgG (20 mg/ml) in the absence or presence of TGF-b (10
ng/ml), TNF-a (10 ng/ml), or LPS (10 mg/ml). Collagen production by
these cells was determined by incorporation of [3H]proline into colla-
genase sensitive peptides as described under “Materials and Methods.”
Addition of IL-10 antibodies alone resulted in a 50% increase in basal
collagen production (Control) by HSC. TGF-b-mediated up-regulation of
collagen production was enhanced by 2-fold by IL-10 neutralization.
TNF-a or LPS, which did not stimulate HSC collagen production by
itself, caused significant enhancement of collagen production if added
together with anti-IL-10 IgG. *, p , 0.05.
FIG. 3. A, representative data for IL-10 competitive PCR for HSC
from rats at 7 days after bile duct ligation (BDL) or sham operation
(Sham). As shown in this example, addition of an IL-10 competitor
concentration-dependently suppressed the level of IL-10 PCR product
while it increased the level of the competitor product in both samples
from Sham and BDL animals. However, the BDL sample required
higher concentrations of the competitor to suppress generation of IL-10
product than the Sham sample, indicating the higher IL-10 mRNA level
in the BDL sample. B, data from three sets of competitive PCR were
plotted and a linear regression analysis was performed. Arrows indicate
the estimated levels of IL-10 mRNA as determined by the concentration
of the competitor, which achieved generation of the equal amount of
IL-10 and competitor products (the ratio of IL-10 over competitor prod-
uct 5 1). Note the estimated increase in IL-10 mRNA in BDL HSC is
100-fold.
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TGF-b (10 ng/ml), TNF-a (10 ng/ml), and LPS (10 mg/ml) in the
presence of anti-IL-10 IgG or nonimmune IgG (Fig. 6). The
addition of anti-IL-10 IgG alone caused a 50% increase in basal
collagen production. TGF-b-mediated stimulation of collagen
production was doubled by the addition of the antibodies. Even
though TNF-a or LPS alone did not increase collagen produc-
tion, concomitant IL-10 neutralization resulted in significant
enhancements in collagen synthesis. These results clearly dem-
onstrate an inhibitory autocrine effect of IL-10 on collagen
synthesis by culture-activated HSC.
IL-10 Neutralization Affects a1(I) Collagen and Collagenase
mRNA Expression—To investigate mechanisms underlying the
observed inhibitory role of IL-10 in HSC collagen production,
we have examined effects of IL-10 neutralization on mRNA
expression of a1(I) collagen and interstitial collagenase by cul-
tured HSC. Exposure of HSC to TNF-a (10 ng/ml) or LPS (10
mg/ml) stimulated mRNA expression of collagenase (Fig. 7,
upper left panel). However, addition of anti-IL-10 IgG clearly
suppressed these stimulatory effects (Fig. 7, upper right panel).
TGF-b (10 ng/ml) stimulated a1(I) collagen mRNA expression
in cultured HSC and LPS marginally showed the effect (Fig. 7,
upper panel). Addition of anti-IL-10 antibodies further pro-
moted the increases in a1(I) collagen mRNA levels in TGF-b- or
LPS-stimulated HSC (Fig. 7, upper panel). Densitometric data
from at least three sets of experiments were standardized with
b-actin results and statistically compared between the differ-
ent treatments (Fig. 7, lower panel). Addition of anti-IL-10
antibodies slightly, but significantly, reduced basal interstitial
collagenase mRNA expression. Furthermore, it suppressed an
increase in interstitial collagenase mRNA levels induced by
TNF-a and LPS (Fig. 7, lower left panel). On the contrary, IL-10
neutralization significantly enhanced by 2-fold the increase in
a1(I) collagen mRNA expression by HSC exposed to TGF-b and
LPS (Fig. 7, lower right panel). These results suggested that
IL-10 secreted by culture-activated HSC not only induces basal
expression of collagenase but also mediates up-regulation of
collagenase expression caused by TNF-a and LPS. At the same
time, IL-10 expression induced by TGF-b and LPS appears to
exert an inhibitory effect on a1(I) collagen expression.
IL-10 Suppresses COLL Promoter Activity—To examine
whether the observed inhibitory effect of IL-10 on collagen
expression is mediated via its effect at transcriptional level,
transient co-transfections were performed using an IL-10 ex-
pression vector (sense or antisense) with an a1(I) collagen
promoter-luciferase construct (pGLCO2 or pGLCO3). As com-
pared with transfection with the antisense IL-10 expression
vector, collagen promoter activity was inhibited 40% with the
sense IL-10 expression vector (Fig. 8). This suggests that IL-
10’s negative autoregulatory effects on HSC collagen expres-
sion is mediated at least in part via its transcriptonal inhibition
of collagen gene.
FIG. 7. Upper panel, RT-PCR for a1(I) collagen and interstitial collagenase mRNA in cultured HSC incubated with anti-IL-10 IgG. TNF-a (10
ng/ml)- or LPS (10 mg/ml)-stimulated collagenase mRNA expression by HSC (upper left, first panel), and this stimulation was suppressed by
anti-IL-10 IgG (upper right, first panel). TGF-b (10 ng/ml) increased a1(I) collagen mRNA level (upper left, second panel), and this effect was further
promoted by IL-10 neutralization (upper right, second panel). LPS (10 mg/ml), which marginally stimulated HSC a1(I) collagen mRNA expression
alone, caused a distinct stimulatory effect if anti-IL-10 IgG is concomitantly added (upper right, second panel). Lower panels, densitometric analysis
of RT-PCR data for interstitial collagenase and a1(I) collagen mRNA expression. Note anti-IL-10 IgG suppresses TNF-a- and LPS-stimulated
interstitial collagenase mRNA expression by cultured HSC in addition to its inhibition of basal collagenase mRNA levels. *, p , 0.05 compared with
HSC incubated with nonimmune IgG. Also note anti-IL-10 antibodies promote 2-fold the increased a1(I) collagen mRNA expression induced by
TGF-b (10 ng/ml). Even though LPS (10 mg/ml) alone did not significantly increase a1(I) collagen mRNA levels, concomitant treatment of the cells
with anti-IL-10 IgG caused a significant stimulation of a1(I) collagen mRNA expression.
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DISCUSSION
The present study is the first to demonstrate that HSC
express IL-10 upon their activation in vivo and in vitro. HSC
are considered as pericytes in the liver (40), which are also
known to serve as principal cells to participate in liver fibro-
genesis via their myofibroblastic activation (1). A recent report
demonstrated expression of IL-10 by mesangial cells, the peri-
cytes in the glomerulus, which are incriminated as the major
source of fibroproliferative responses in glomerulonephritis
(41). Since HSC and mesangial cells are considered analogous
due to their similar functionality and pathophysiologic roles,
we hypothesized that HSC may express IL-10. Our results
demonstrate IL-10 is expressed by HSC upon activation in
culture and during the early stage of biliary liver injury. Our
RT-PCR specificity was verified by sequencing of the IL-10
PCR product, with which we further confirmed induced mRNA
expression via Northern blot analysis. Western blot analysis of
HSC protein extracts revealed a prominently expressed 17-kDa
IL-10 protein at 7 days after BDL, and the cultured HSC were
shown to express and release IL-10 in response to TNF-a,
TGF-b, and LPS.
Our previous work showed enhanced expression of TNF-a by
hepatic macrophages at 1 and 2 weeks after BDL but an almost
complete disappearance of such induction at 3 weeks (42).
Since our in vitro experiment demonstrates induction of IL-10
in HSC by TNF-a, it may be assumed that macrophage-derived
TNF-a in the liver might have induced IL-10 expression by
HSC in the time-dependent manner in the BDL model. How-
ever, the concomitant induction (7 days) and repression (19
days) of macrophage TNF-a and HSC IL-10 expression in this
in vivo model also suggest IL-10 derived from HSC may not
function as an anti-inflammatory cytokine toward hepatic
macrophages. This assumption led us to think of other biolog-
ical significance that HSC-derived IL-10 may possesses in the
liver. To this end, we were intrigued by recent studies that
showed IL-10-mediated regulation of the genes involved in
matrix remodeling and homeostasis such as MMP-1, MMP-3,
MMP-9, TIMP-1, and a1(I) collagen in skin fibroblasts (28) and
macrophages (29). Indeed, our culture study clearly demon-
strates IL-10 released by HSC suppresses their collagen pro-
duction and this effect is mediated at least in part by transcrip-
tional inhibition of collagen gene and enhanced expression of
interstitial collagenase. These findings suggest a negative au-
toregulatory role of IL-10 in HSC collagen production in matrix
remodeling. In support of this view, our in vivo data reveals
concomitant induction of IL-10 and interstitial collagenase in
HSC during the early stage of cholestatic liver fibrosis (7 days
after BDL) and the lack of HSC IL-10 expression in association
with marked a1(I) collagen induction in advanced liver fibrosis
at 19 days. This raises an intriguing secondary hypothesis that
the failure of HSC to continue their expression of IL-10 may
underlie progressive fibrogenesis leading to liver cirrhosis.
Interplay between soluble factors of paracrine and autocrine
sources is complex in regulation of HSC biology. Among several
cytokines implicated in activation of HSC, TGF-b is considered
a potent fibrogenic cytokine that seems capable of conferring
HSC most aspects of cellular activation (3–8). This cytokine
can be released by hepatic macrophages (9) or HSC by them-
selves (15), and the paracrine and autocrine interaction can be
established via its ability to autoinduce its expression (15). In
our in vitro study, TGF-b induced IL-10 in cultured HSC.
However, IL-10 induction was abolished in HSC at 19 days
after BDL despite HSC (43) and hepatic macrophages2 con-
tinue to express TGF-b1 at this time point in this model. Thus,
unlike the close in vivo association between IL-10 and TNF-a
expression in the BDL model, this dissociation of IL-10 and
TGF-b expression suggests complex regulation of IL-10 expres-
sion by TGF-b. Another discrepancy noted in the present study
was the continued induction of IL-10 expression by culture-
activated HSC as compared with the time-dependent induction
seen in vivo. This obviously suggests cellular or molecular
differences in in vitro and in vivo activated HSC or reflects the
absence of other in vivo factors that may cause the time-de-
pendent expression in the culture system. It is attractive to
speculate that these factors may be derived from other cell
types in the liver including hepatic macrophages. Additional
studies are obviously needed to test this hypothesis.
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